Oversubscribed round led by Foresite CapitalFunding will enable development of DNA synthesis chip technology to commercial scale
Cambridge, UK 07 February 2023– EVONETIX LTD (‘Evonetix’), the synthetic biology company bringing semiconductor technology to DNA synthesis, today announced it has completed a USD $24 million financing round, extending its total series B funding to over USD $54 million (circa GB £44 million). This fundraise was led by existing investor Foresite Capital, with Molten Ventures, Morningside, DCVC, Cambridge Consultants, Civilization Ventures and Providence also…
We are today pleased to share the annual trading update for Bruntwood SciTech for 2022, which includes an overview of the £91m capital investment we confirmed last year. Very positively, it is our best performing year since forming in a partnership between Bruntwood and Legal & General in 2018, and we have and will continue to display an unwavering commitment to further cement the UK's position as an R&D powerhouse this year and beyond.
View the results via the links below.
Twitter: https://twitter.com/BW_SciTech/status/1622505938354688000
LinkedIn: https://www.linkedin.com/…
Apply for the Primer Fund
Are you developing a solution to accelerate the diagnosis of MND? We're seeking proposals for funding in the areas of point of care diagnostic markers, digital markers of early symptoms and algorithmic approaches applied to pt data to detect changes indicative of MND. Proposals welcome from academia and industry. Deadline 20th Feb.
York, UK (January 31, 2023) – Aptamer Group plc (AIM: APTA), the developer of novel Optimer® binders to enable innovation in the life sciences industry, today announces a new partnership with BaseCure Therapeutics for the development of Optimer-targeted gene therapies. The ability to precisely target gene therapies, like siRNA-based therapeutics, to specific cells and tissues using Optimers offers exciting new opportunities for the field of gene therapy.
BaseCure Therapeutics is a pre-clinical stage biotech company dedicated to the discovery and development of innovative siRNA-based…
Become a mentor for a rare disease patient group leader who needs YOU and your skills!
This is your chance to give something back to a community that has given so much to those living with a rare disease.
Not sure what skills or advice you have to offer? Just being a sounding board for patient group leaders is invaluable. You don’t need to have a background in rare diseases! You simply need to encourage and guide patient group leaders as they identify the support they need, help them fully evaluate their options and empower them to uncover new information to help them reach their goals.
Never…
Arecor Therapeutics plc
(“Arecor”, the “Company” or the “Group”)
ARECOR ANNOUNCES PUBLICATION OF PHASE I DATA FOR AT278 IN DIABETES CARE
- Ultra-concentrated, ultra-rapid acting insulin AT278, a promising candidate in the pursuit of next generation insulins to simplify and improve glycemic control
Cambridge, UK, 30 January 2023: Arecor Therapeutics plc, a globally focused biopharmaceutical company advancing today’s therapies to enable healthier lives, today announces that the American Diabetes Association journal, Diabetes Care, has published data from the Company’s Phase I clinical trial of…
ValiRx PLC, a life science company focused on early-stage cancer therapeutics and women's health, has taken the lease on laboratory and office facilities at MediCity Nottingham as it embarks on the next stage of its strategy to launch a translational Contract Research Organisation (tCRO).
Based in Beeston, MediCity is a medtech incubator and part of Pioneer Group, and provides resident businesses with access to a connected local and national biotech community, a strong pool of quality talent from nearby universities, and flexible laboratory space.
ValiRx’s new facilities include 910 sq…
Cambridge UK: December 2022
PCML Group continues partnership with One Nucleus to develop engagement with One Nucleus and its members. The One Nucleus Partner Programme is tailor-made to meet the needs of the Partner and One Nucleus members.
Lee Carlin, Commercial Director of the PCML Group: ‘Following our successful collaboration with One Nucleus in 2022, we hope that our continued partnership will deepen our understanding of the challenges faced in the development and manufacture of Life Science and Biomedical technology and we can continue to support members within the One Nucleus…
Following a forecast 0.3% decline in GDP in Q3, the UK economy is expected to contract around 0.2% each quarter from Q4 this year through to Q2 2023, resulting in GDP falling 0.3% in 2023 as a whole. This is a significant revision from the 1% growth forecast for 2023 in the EY ITEM Club’s July Summer Forecast – although the scale of the upcoming downturn is expected to be shallow relative to previous recessions thanks, in part, to the Government’s intervention on household and business energy bills.
As the squeeze on real incomes from high inflation eases, tax cuts take effect, the cheap…